期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性丙型肝炎治疗的最新研究进展 被引量：3

下载PDF
导出
摘要 据世界卫生组织统计,全球丙型肝炎病毒（HCV）的感染率约为3%,估计约1.7亿人感染HCV,每年新发丙型肝炎病例约3.5万例.我国一般人群抗-HCV阳性率为3.2%,HCV感染是导致肝硬化和肝细胞癌的一个重要原因[1].在过去的十年中,聚乙二醇干扰素联合利巴韦林治疗已成为治疗HCV基因型慢性丙型肝炎的标准抗病毒治疗方案,虽然聚乙二醇干扰素联合利巴韦林的标准治疗方案较先前的普通干扰素联合利巴韦林治疗或聚乙二醇干扰素单一疗法取得更好的应答率,但是仍有高比例的患者遭受治疗失败或治疗的副作用而终止治疗.为此,笔者根据最近更新的美国肝病学会（AASLD）和欧洲肝病学会（EASL）慢性丙型肝炎的实践指南[2-4],对影响丙型肝炎治疗的因素、应答指导治疗、标准治疗失败后的再治疗、治疗过程中不良事件的处理和新型抗HCV药物的最新研究进展进行了综述.
作者 谢能文 何金秋
机构地区 南昌市第九医院肝病科
出处 《南昌大学学报（医学版）》 CAS 2013年第12期94-97,共4页 Journal of Nanchang University：Medical Sciences
关键词 慢性丙型肝炎 聚乙二醇干扰素 利巴韦林 应答指导治疗
分类号 R512.63 [医药卫生—内科学]
  • 相关文献

参考文献27

  • 1丙型肝炎防治指南[J].中华传染病杂志,2004,22(2):131-136. 被引量：225
  • 2Ghany M G, Strader D B,Thomas D L, et al. American Associ- ation for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C:an update[J]. Hepatology, 2009, 49(4) :1335-1374. 被引量：1
  • 3Ghany M G,Nelson D R,Strader D B,et al. American Associ- ation for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases[J]. Hepatology, 2011,54 (4) : 1433-1444. 被引量：1
  • 4European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infeeti- on[J]. J Hepatol,2011,55(2) :245-264. 被引量：1
  • 5Afdhal N H,Mc Hutchison J G,Zeuzem S,et al. Hepatitis C pharmacogenetics:state of the art in 2010 [J].Hepatology,2011,53(1) :336-345. 被引量：1
  • 6Tillmann H L,Thompson A J,Patel K,et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice[J]. Gastroenterology, 2010,139 (5) : 1586-1592. 被引量：1
  • 7Liao X W,Ling Y,Li X H,et al. Association of genetic varia- tion in IL28B with hepatitis C treatment-induced viral clear- ance in the Chinese Han population[J]. Antivir Ther, 2011,16 (2) :141-147. 被引量：1
  • 8谢尧,李明慧.慢性丙型肝炎标准抗病毒治疗的新时代[J].实用肝脏病杂志,2012,15(5):384-386. 被引量：13
  • 9Ruiz Extremera A,Munoz Gdmez J A,Salmer6n Ruiz M A, et a]. Genetic variation in interleukin 28B with respect to vertical transmission of hepatitis C virus and spontaneous clearance in HCV-infected children [J]. Hepatology, 2011, 53 ( 3 ) : 1830- 1838. 被引量：1
  • 10Legrand Ahravanel F, Colson P, Leguillou Guillemette L, et al. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy[J].J Med Virol, 2009,81(12) :2029-2035. 被引量：1

二级参考文献25

  • 1康来仪,孙永德,郝连杰,曹学义,潘启超.我国丙型和戊型肝炎人群流行病学调查及流行因素的研究[J].中华传染病杂志,1997,15(2):71-75. 被引量：99
  • 2Shepard CW, Finelli L, Mter MJ. Global epidemiology of hepatitis C vires infection[J]. Lancet Infect Dis, 2005, 5(9):558-567. 被引量：1
  • 3Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes[J]. Hepatology, 2005, 42(4):962-973. 被引量：1
  • 4Nakano T, Lu L, He Y, et al. Population genetic history of hepatitis C virus lb infection in China[J]. J Gen Virol, 2006, 87(Pt 1): 73-82. 被引量：1
  • 5European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection[J]. J Hepatol, 2011, 55(2):245-264. 被引量：1
  • 6Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection[J]. N Engl J Med, 2011,364(25):2417-2428. 被引量：1
  • 7Franeiscus A. Hepatitis C treatment in current clinical development[EB/OL]. [2012-12-01]. http://www.hcvadvocate.org/hepatitis/. 被引量：1
  • 8Chung RT. Hepatitis debrief[J]. Hepatology, 2012, 56(S4):84A. 被引量：1
  • 9Poordad F, Lawitz E, Reddy R, et al. Timing and magnitude of ribavirin dose reduction (RBV DR) do not impact sustained virologic response (SVR) rates with boceprevir (BOC)+peginterferon alfa-2b/ ribavirin (PEG/RBV) in the anemia management study in chronic HCV genotype 1 patients[J]. Hepatolugy, 2012, 56($4):269A. 被引量：1
  • 10Hassanein T, Lawitz E, Crespo I, et al. Once daily sofosbuvir [GS- 7977] plus REG/RBV: high early response rates are maintained during post-treatment follow-up in treatment-naive patients with HCV genotype 1, 4, and 6 intection in the ATOMIC Study [J]. Hepatology, 2012, 56($4):307A. 被引量：1

共引文献243

同被引文献75

  • 1Takanori Hosokawa,Masayuki Kurosaki,Kaoru Tsuchiya,Shuya Matsuda,Masaru Muraoka,Yuichiro Suzuki,Nobuharu Tamaki,Yutaka Yasui,Toru Nakata,Takashi Nishimura,Shoko Suzuki,Ken Ueda,Hiroyuki Nakanishi,Jun Itakura,Yuka Takahashi,Namiki Izumi.Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy[J].World Journal of Gastroenterology,2013,19(2):249-257. 被引量：12
  • 2蒋思卿,彭大为,何立香.调节性T细胞与肝癌的研究进展[J].中南大学学报（医学版）,2015,40(4):433-437. 被引量：2
  • 3Raja N S.Janjua K A. Epidemiology of hepatitis C virus infec-tion in Pakistan[J]. J Microbiol Immunol Infect,2008,41(1):4-8. 被引量：1
  • 4Gawlik K,Baugh J,Chatterji U,et al. HCV core residues criti-cal for infectivity are also involved in core-NS5A complex for-mation[J], PLoS One,2014,9(2) :e88866. 被引量：1
  • 5Liu J, Ding X,Tang J,et al. Enhancement of canonical Wnt/^-catenin signaling activity by HCV core protein promotes cellgrowth of hepatocellular carcinoma ceilsQ], PLoS One,2011,6(ll):e27496. 被引量：1
  • 6Goffard A,Callens N.Bartosch B,et al. Role of N-linked glycans inthe functions of hepatitis C virus envelope giycoproteins[J]. J Vir-ol,2005,79(13) :8400-8409. 被引量：1
  • 7Scarselli E* Ansuini H * Cerino R,et al. The human scavengerreceptor class B type I is a novel candidate receptor for thehepatitis C virus[J]. EMBO J,2002,21( 19) :5017-5025. 被引量：1
  • 8Mazumdar B,Banerjee A,Meyer K,et al. Hepatitis C virus Elenvelope glycoprotein interacts with apolipoproteins in facilita-ting entry into hepatocytes[J]. Hepatology,2011,54(4) s 1149-1156. 被引量：1
  • 9Boulestin A,Sandres Saune K,Payen J L,et al. Genetic hetero-geneity of the envelope 2 gene and eradication of hepatitis C vi-rus after a second course of interferon-alpha[J]. J Med Virol,2002,68(2):221-228. 被引量：1
  • 10Gan S W, Surya W. Vararattanavech A, et al. Two differentconformations in hepatitis C virus p7 protein account for pro-ton transport and dye release [J]. PLoS One, 2014 . 9(1):e78494. 被引量：1

引证文献3

二级引证文献11

南昌大学学报（医学版）
2013年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部